NCT02487979 2022-01-18
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
4 trialsNCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT01997333 2019-03-08
METRIC
Celldex Therapeutics
Phase 2 Completed
NCT01156753 2017-07-02
EMERGE
Celldex Therapeutics
Phase 2 Completed